Griseofulvin Brown & Burk Uk (Griseofulvin)

Griseofulvin Brown & Burk UK is indicated for the treatment of dermatophytic infections caused by susceptible fungi.

• Tinea corporis (ringworm of the body)
• Tinea capitis (scalp ringworm)
• Tinea pedis (athlete’s foot)
• Tinea cruris (jock itch)
• Other superficial dermatophytoses such as tinea barbae or tinea unguium when oral therapy is required

Side effects reported with oral griseofulvin vary in frequency and severity.

Common

• Headache, which may be mild to moderate in intensity.
• Nausea, vomiting, or upset stomach that can affect appetite.
• Skin rash or mild irritation, often transient.
• Increased sensitivity to sunlight, leading to easy sunburn.

Serious

• Severe liver injury or hepatitis, presenting with jaundice or elevated enzymes.
• Blood dyscrasias such as agranulocytosis or aplastic anemia, requiring immediate medical attention.

Before starting Griseofulvin Brown & Burk UK, certain precautions should be considered to minimize risks and ensure safe use.

• Assess liver function because griseofulvin is metabolized hepatically.
• Review the patient’s complete blood count, especially if a history of hematologic disorders exists.
• Use effective contraception; griseofulvin may reduce hormonal contraceptive efficacy.
• Advise patients to avoid excessive sun exposure and to use sunscreen regularly.
• Inform patients about the potential for drug interactions with CYP450 substrates.
• Monitor for signs of allergic reaction during the first weeks of therapy.
• Consider dose adjustment in patients with renal impairment if needed.

Griseofulvin can alter the metabolism of several medications, so awareness of potential interactions is important.

Avoid

• Oral contraceptives, as efficacy may be reduced.
• Warfarin, due to possible increased anticoagulant effect.
• Cyclosporine, because griseofulvin may raise cyclosporine levels.

Use with caution

• Antifungal agents such as itraconazole or ketoconazole, which share metabolic pathways.
• Antiretroviral drugs metabolized by CYP3A4, e.g., protease inhibitors.
• Certain antiepileptic drugs (e.g., phenytoin, carbamazepine) that may have altered levels.